You are here

  • Home
  • Archive
  • Volume 7, Issue Suppl 1
  • O-008 final revascularization and clinical outcome results from the multicenter trevo stent-retriever acute stroke (track) post-marketing registry

Article Text

Article menu
Download PDFPDF
Oral abstracts
SNIS 12th Annual Meeting Oral Abstracts
O-008 final revascularization and clinical outcome results from the multicenter trevo stent-retriever acute stroke (track) post-marketing registry
  1. O Zaidat1,
  2. A Castonguay1,
  3. R Nogueira2,
  4. P Ramakrishnan3,
  5. D Haussen3,
  6. A Lima3,
  7. J English4,
  8. H Farid5,
  9. E Veznedaroglu6,
  10. M Binning6,
  11. A Puri7,
  12. S Hou7,
  13. V Janardhan8,
  14. N Vora9,
  15. R Budzik9,
  16. A Alshekhlee10,
  17. M Abraham11,
  18. R Edgell12,
  19. M Taqi13,
  20. E Lin14,
  21. R Khoury15,
  22. M Mokin16,
  23. A Majjhoo17,
  24. M Kabbani18,
  25. M Froehler19,
  26. I Finch20,
  27. S Prabhakaran21,
  28. R Novakovic22,
  29. T Nguyen23,
  30. J Wesley1
  1. 1Medical College of Wisconsin, Milwaukee, WI, , USA
  2. 2Emory Univeristy School of Medicine, Atlanta, GA, USA
  3. 3Emory University School of Medicine, Atlanta, GA, USA
  4. 4California Pacific Medical Center, San Francisco, CA, USA
  5. 5St. Jude Medical Center, Chicago, IL, USA
  6. 6Capital Health Institute for Neurosciences, Pennington, NJ, USA
  7. 7University of Massachusetts Medical School, Worcester, MA, USA
  8. 8Texas Stroke Institute, Plano, TX, USA
  9. 9Riverside Radiology, Columbus, OH, USA
  10. 10SSM Neuroscience Institutes, DePaul Health, St. Louis, MO, USA
  11. 11University of Kansas, Kansas City, KS, USA
  12. 12St. Louis University Hospital, St. Louis, MO, USA
  13. 13Desert Regional Medical Center, Palm Springs, CA, USA
  14. 14Baptist Cardiac and Vascular Institute, Miami, FL, USA
  15. 15Tulane University School of Medicine, New Orleans, LA, USA
  16. 16University of South Florida, Tampa, FL, USA
  17. 17Wayne State University School of Medicine, Detroit, MI, USA
  18. 18Gundersen Lutheran Medical Foundation, Inc., La Crosse, WI, USA
  19. 19Vanderbilt University Medical Center, Nashville, TN, USA
  20. 20John Muir Medical Center, Walnut Creek, CA, USA
  21. 21Northwestern University, Evanston, IL, USA
  22. 22University of Texas Southwestern Medical Center, Dallas, TX, USA
  23. 23Boston Medical Center, Boston, MA, USA

Abstract

Background Real life practice can differ significantly from  criteria in randomized clinical trials (RCT), including patient population, treatment criteria, and broader treatment times.  Distinguishing device performance in these two different  scenarios is critical in applying RCT data to routine clinical practice.

Objective The TREVO Stent-Retriever Acute Stroke (TRACK) Registry aimed to assess the real-world safety, angiographic, and clinical efficacy of the TREVO device in comparison to the results from the TREVO-2 clinical trial.

Design/methods The TRACK Registry recruited clinical sites within the USA. Demographic, clinical, angiographic, and outcome data on patients treated with the TREVO device were  collected. Symptomatic intracranial hemorrhage (sICH) was defined as any parenchymal hematoma, SAH, or IVH associated with a worsening of the NIHSS score by≥4 within 24 h. The  primary outcome was achieving TICI≥2a revascularization.  Secondary outcomes were mRS at 3 months, mortality, and sICH.

Results 23 centers contributed data on 586 patients for the final analysis. Baseline demographics were: 48.6% female, 68.3% white, mean age 65.8 ± 14.9 years, median baseline NIHSS of 17 (IQR 13–22), M1 (54.2%)/ICA(17.1%)/VB(13.7%) occlusion, IV-tPA use 50.4%, general anesthesia 63.2%, balloon guide  catheter use 47.0%, mean fluoroscopic time 26.2 ± 22.1 min, and a median revascularization time of 65.5 (IQR 37–105.75) minutes.

The TICI ≥2a and TICI ≥2b revascularization rates were 92.4% (537/581) and 80.4% (467/581), compared to the operator reported TICI ≥ 2a rate of 85% and core laboratory adjudicated TICI ≥2b of 68% in TREVO-2. Good outcome (mRS≤2) was demonstrated in 48.3% (240/497), compared to 40% (TREVO-2). The rate of sICH was 7.5% (43/574), compared to 4% (TREVO-2). 90-day mortality was 20.1% (100/497) versus 29% in TREVO-2.

Multivariate logistic regression analysis demonstrated that younger patients, lower baseline NIHSS, revascularization success (TICI ≥2B), and use of conscious sedation were independent predictors of good clinical outcome. Independent predicators of mortality included older patients, higher baseline NIHSS, vertebral-basilar occlusion, lack of IV-tPA use, failure to achieve revascularization, and sICH.

Conclusion The investigator-initiated TRACK Registry demonstrates that the post-marketing TREVO stent-retriever performance in routine clinical practice is comparable to the TREVO-2 trial, with improved revascularization success, good outcome, and decreased mortality.

Disclosures O. Zaidat: 1; C; Stryker, Covidien. 2; C; Stryker, Covidien. A. Castonguay: None. R. Nogueira: None. P. Ramakrishnan: None. D. Haussen: None. A. Lima: None. J. English: None. H. Farid: None. E. Veznedaroglu: None. M. Binning: None. A. Puri: None. S. Hou: None. V. Janardhan: None.  N. Vora: None. R. Budzik: None. A. Alshekhlee: None. M. Abraham: None. R. Edgell: None. M. Taqi: None. E. Lin: None. R. Khoury: None. M. Mokin: None. A. Majjhoo: None. M. Kabbani: None. M. Froehler: None. I. Finch: None. S. Prabhakaran: None. R. Novakovic: None. T. Nguyen: None. J. Wesley: None.

https://doi.org/10.1136/neurintsurg-2015-011917.8

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.